



et al., Zheng, Y., Huang, T., Paternoster, L., Sørensen, T. I. A., & Qi, L. (2020). Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood. *European Journal of Epidemiology*.
<https://doi.org/10.1007/s10654-020-00638-z>

Peer reviewed version

Link to published version (if available):
[10.1007/s10654-020-00638-z](https://doi.org/10.1007/s10654-020-00638-z)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Springer Nature at <https://link.springer.com/article/10.1007/s10654-020-00638-z>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Genetic evidence does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood

Yan Zheng,^{1, 2*#} Tao Huang,^{3*} Tiange Wang,^{4,5*} Zhendong Mei,¹ Zhonghan Sun,¹ Christina Ellervik,^{6, 7} Jin-Fang Chai,⁸ Tarunveer S. Ahluwalia,^{9,110} Rebecca K. Vinding,⁹ Hans Bisgaard,⁹ Tine Marie Pedersen,⁹ Lise Tarnow,¹⁰ Yujie Wang,¹¹ Trudy Voortman,¹² Frank van Rooij,¹² Raymond Noordam,¹³ Angela C. Estampador,¹⁴ Tibor V. Varga,¹⁴ Paul W. Franks,¹⁴ Markus Scholz,^{15, 16} Emily Sonestedt,¹⁷ Masato Akiyama,¹⁸ Rajkumar Dorajoo,¹⁹ Ang Zhou,²⁰ Tuomas O. Kilpeläinen,²¹ Marcus E Kleber,^{22, 23, 24} Sarah Crozier,²⁵ Mark McCarthy,²⁶ Rozenn Lemaitre,²⁷ Janine F Felix,^{28, 29, 30} Yuan Shi,³¹ Preeti Gupta,³¹ Chiea-Chuen Khor,¹⁹ Ying Wu,³² Terho Lehtimäki,^{33, 34} Carol A. Wang,³⁶ Heribert Schunkert,³⁷ Christian Hengstenberg,³⁷ Thorsten Kessler,³⁷ Lars Bertram,³⁷ Lingyao Zeng,³⁷ Ilja Demuth,³⁷ Thomas Meitinger,³⁸ Annette Peters,³⁸ Wolfgang Lieb,³⁸ Peter Rzehak,³⁹ Jeanette Erdmann,⁴⁰ Christina Willenborg,⁴⁰ Matthias Munz,⁴⁰ Meian He,⁴¹ Cécile Lecoeur,^{42, 43} Dolores Corella,^{44, 45} Chao-Qiang Lai,⁴⁶ Luis A Moreno,^{45, 47} Niina Pitkänen,⁴⁸ Colin A Boreham,⁴⁹ Tao Zhang,^{3, 50} Seang Mei Saw,^{8, 31} Paul M Ridker,⁵¹ Mariaelisa Graffl Andre G. Uitterlinden,⁵² Albert Hofman,^{12, 53} Diana van Heemst,¹³ Frits R Rosendaal,⁵⁴ Renée de Mutsert,⁵⁴ Andrej Teren,^{16, 55} Ralph Burkhardt,^{16, 35, 56} Christina-Alexandra Schulz,¹⁷ Ulrika Ericson,¹⁷ Cornelia Enzenbach,^{15, 16} Yoichiro Kamatani,¹⁸ Jian-Min Yuan,^{57, 58} Chris Power,⁵⁹ Torben Hansen,²¹ Lavinia Paternoster,⁶⁰ Torben Hansen,²¹ Thorkild IA Sørensen,^{21, 60, 61} Anne Tjønneland,⁶² Kim Overvad,^{63, 64} Graciela Delgado,²² Cyrus Cooper,^{25, 65} Luc Djousse,⁶⁶ Fernando Rivadeneira,^{28, 29, 67} Karen Jameson,²⁵ Wanting Zhao,³¹ Shu Pei Tan,³¹ Jianjun Liu,^{8, 19} Nanette R. Lee,^{68, 69} Linda S. Adair,⁷⁰ Olli Raitakari,^{48, 71} Mika Kähönen,^{72, 73} Jorma Viikari,^{74, 75} Craig E. Pennell,³⁶ Veit Grote,³⁹ Jean-Paul Langhendries,⁷⁶ Berthold Koletzko,³⁹ Joaquin Escribano,⁷⁷ Elvira Verduci,⁷⁸ George Dedoussis,⁷⁹ Inke König,⁸⁰ Caizheng Yu,⁴¹ Philippe Froguel,^{42, 43, 81} Beverley Balkau,^{82, 83, 84} Oscar Coltell,^{45, 85} Jean Dallongeville,⁸⁶ Frédéric Gottrand,⁸⁷ Katja Pakkala,^{48, 88} Harri Niinikoski,^{89, 90} Elina Hyppönen,^{59, 91, 92} Oluf Pedersen,²¹ Winfried März,^{22, 93, 94} Hazel Inskip,^{25, 26} Vincent WV Jaddoe,^{28, 29, 30} Elaine Dennison,^{25, 95} Tien Yin Wong,^{31, 96} Charumathi Sabanayagam,^{31, 96} E-Shyong Tai,^{8, 97, 98} Karen L. Mohlke,³² Vera Mikkilä,⁹⁹ David Mackey,¹⁰⁰ Dariusz Gruszfeld,¹⁰¹ Yik-Ying Teo,¹⁰² Katherine L. Tucker,¹⁰³ Frédéric Fumeron,^{104, 105, 106} Klaus Bønnelykke,⁹ Ramon Estruch,^{45, 107} Jose M. Ordovas,^{46, 108} Donna K. Arnett,¹⁰⁹ Peter Rossing,¹¹⁰ Aline Meirhaeghe,⁸⁶ Philippe Amouyel,⁸⁶ Xueling Sim,⁸ Rob M. van Dam,⁸ Woon-Puay Koh,^{8, 98} Marju Orho-Melander,¹⁷ Markus Loeffler,^{15, 16} Michiaki Kubo,¹⁸ Joachim Thiery,^{16, 56} Dennis O Mook-Kanamori,^{54, 111} Dariush Mozaffarian,¹¹² Bruce M Psaty,^{27, 113, 114, 115} Oscar H Franco,¹² Tangchun Wu,⁴¹ Kari E. North,^{11, 116} Daniel I Chasman,^{51, 66} Lu Qi^{5#}

* Contributed equally to this work

1. Department of Cardiology Zhongshan Hospital, State Key Laboratory of Genetic Engineering School of Life Sciences, Human Phenome Institute, Fudan University.
2. Key Laboratory of Public health safety of ministry of education, School of public health, Fudan university.
3. Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
4. Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
5. Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
6. Affiliate Associate Research Professor, University of Copenhagen, Denmark & Assistant Professor, Harvard Medical

School, Boston, USA

7. Consultant Physician, Department of Production, Research and Innovation, Region Zealand, Denmark & Associate Director of Clinical Chemistry, Boston Children's Hospital, USA
8. Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117549.
9. COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
10. Department of Clinical Research, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark
11. Department of Epidemiology, University of North Carolina, Chapel Hill, NC, 27514, USA.
12. Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
13. Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands.
14. Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Skåne University Hospital Malmö, SE-21741, Malmö, Sweden
15. Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
16. Institute for Laboratory Medicine, University of Leipzig, Leipzig, Germany
17. Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
18. RIKEN Center for Integrative Medical Sciences, Laboratory for Statistical Analysis. Japan.
19. Genome Institute of Singapore, Agency for Science Technology and Research, Singapore.
20. Centre for Population Health Research, School of Health Sciences and Sansom Institute of Health Research, University of South Australia, Adelaide, Australia.
21. The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark.
22. Vth Department of Medicine, Mannheim Medical Faculty, Heidelberg University, Mannheim, Germany.
23. Institute of Nutrition, Friedrich Schiller University Jena, Germany.
24. Competence Cluster of Nutrition and Cardiovascular Health (nutriCARD) Halle-Jena-Leipzig, Germany.
25. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton. SO16 6YD. UK.
26. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ UK
27. Cardiovascular Health Research Institute, Department of Medicine, University of Washington, Seattle, WA 98101, USA.
28. The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
29. Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
30. Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
31. Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
32. Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA.
33. Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland
34. Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere 33014, Finland
35. Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany
36. School of Medicine and Public Health, Faculty of Medicine and Health, The University of Newcastle, Callaghan NSW 2308, Australia.
37. Deutsches Herzzentrum München, Technische Universität München, Germany
38. Institute of Epidemiology and PopGen Biobank, Kiel University, Kiel, Germany
39. Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital, Klinikum der Universität

Muenchen, Munich, Germany.

40. Institute for Integrative and Experimental Genomics, University of Lübeck, Germany
41. MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, Hubei, China.
42. University of Lille Nord de France, Lille, France, CNRS UMR8199.
43. Institut Pasteur de Lille, Lille, France.
44. Department of Preventive Medicine and Public Health, University of Valencia, Valencia, 46022, Spain.
45. CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, 28029, Spain.
46. USDA ARS, Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA.
47. Growth Exercise, Nutrition and Development (GENUD) Research Group,, Facultad de Ciencias de la Salud, Universidad de Zaragoza, Zaragoza, Spain.
48. Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku 20520, Finland.
49. UCD Institute for Sport & Health, University College Dublin, Dublin, Ireland.
50. Department of Biostatistics, School of Public Health, Shandong University, Jinan 250012, China.
51. Division of Preventive Medicine, Brigham & Women's Hospital, Boston, MA 02215, USA.
52. Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
53. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
54. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
55. Heart Center Leipzig Leipzig, Germany.
56. LIFE Research Center for Civilisation Diseases, University of Leipzig, Leipzig, Germany
57. Division of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA.
58. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
59. Population, Policy and Practice, UCL Institute of Child Health, London, UK.
60. MRC Integrative Epidemiology Unit & School of Social and community Medicine, University of Bristol, Bristol, BS82BN, UK.
61. Department of Public Health, Section of Epidemiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200N, Denmark.
62. Danish Cancer Society Research Center Copenhagen 2100, Denmark.
63. Department of Public Health, Section for Epidemiology, Aarhus University, DK-8000 Aarhus C, Denmark.
64. Aalborg University Hospital DK-9000 Aalborg, Denmark.
65. Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, The Botnar Research Centre, University of Oxford, Oxford, UK.
66. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston USA.
67. Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
68. USC-Office of Population Studies Foundation, Inc., University of San Carlos, Cebu City 6000, Philippines.
69. Department of Anthropology, Sociology, and History, University of San Carlos, Cebu City 6000, Philippines.
70. Department of Nutrition, University of North Carolina, Chapel Hill, NC 27599, USA.
71. Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku 20521, Finland.
72. Department of Clinical Physiology, Tampere University Hospital, Tampere 33521, Finland.
73. Department of Clinical Physiology, University of Tampere School of Medicine, Tampere 33014, Finland.
74. Division of Medicine, Turku University Hospital, Turku 20521, Finland.
75. Department of Medicine, University of Turku, Turku 20520, Finland.
76. Department of Paediatrics and NICU, CHC-Site St-Vincent, Liège-Rocourt, Belgium.

-
77. Paediatrics Research Unit, Universitat Rovira i Virgili, IISPV, Reus, Spain.
 78. Department of Pediatrics, San Paolo Hospital, University of Milan, Milan, Italy.
 79. Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.
 80. Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Germany
 81. University of Lille Nord de France, Lille, France, CNRS UMR8199.
 82. INSERM, Centre for Research in Epidemiology and Population Health, U1018, F-94807, Villejuif, France.
 83. University Versailles Saint-Quentin-en-Yvelines, UMRS 1018, F-78035, Versailles.
 84. University Paris Sud 11, UMRS 1018, F-94807, Villejuif, France.
 85. Department of Computer Languages and Systems, University Jaume I, Castellon, 12071, Spain.
 86. INSERM U1167, Institut Pasteur de Lille, Univ. Lille, Lille, France.
 87. INSERM U995, Hôpital Jeanne de Flandre, CHU-Lille, Univ. Lille, Lille, France.
 88. Paavo Nurmi Centre, Sports and Exercise Medicine Unit, Department of Physical Activity and Health, Turku, Finland.
 89. Department of Pediatrics, Turku University Hospital, Turku, Finland.
 90. Department of Physiology, University of Turku, Turku, Finland.
 91. Australian Centre for Precision Health, University of South Australia Cancer Research Institute, University of South Australia, Adelaide, Australia.
 92. South Australian Health and Medical Research Institute Adelaide, Australia.
 93. Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim, Germany.
 94. Clinical Institute of Medical and Chemical Laboratory Diagnostics Medical University of Graz, Graz, Austria.
 95. Victoria University of Wellington New Zealand.
 96. Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore.
 97. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
 98. Health Services and Systems Research, Duke-NUS Graduate Medical School, Singapore.
 99. Division of Nutrition, Department of Food and Environmental Sciences, Helsinki 00014, Finland.
 100. Centre for Ophthalmology and Visual Science, Lions Eye Institute, University of Western Australia
 101. Department of Neonatology and Neonatal Intensive Care, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, PL-04-730 Warsaw, Poland.
 102. Saw Swee Hock School of Public Health, National University Health System, National University of Singapore, Singapore
 103. Biomedical and Nutritional Sciences, University of Massachusetts Lowell, Lowell, MA, USA.
 104. INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France.
 105. Univ Paris Diderot, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France.
 106. Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France.
 107. Department of Internal Medicine, Hospital Clinic, IDIBAPS, Barcelona, 08036, Spain.
 108. Department of Epidemiology and Population Genetics, Centro Nacional Investigación, Cardiovasculares (CNIC), Madrid, Spain.
 109. College of Public Health, University of Kentucky, Lexington, KY.
 110. Steno Diabetes Center Copenhagen (SDCC) Niels Steensens Vej 2 DK-2820 Gentofte, Denmark
 111. Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.
 112. Friedman School of Nutrition Science & Policy, Tufts University, Boston, MA 02111, USA.
 113. Department of Epidemiology, University of Washington, WA 98101, USA.
 114. Department of Health Sciences, University of Washington, WA 98101, USA.

115. Kaiser Permanent Washington Health Research Institute, Seattle WA.

116. Carolina Center for Genome Sciences, University of North Carolina, Chapel Hill, NC, 27514, USA.

Correspondences to Lu Qi, Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, Suite 1724, New Orleans, LA 70112, USA. Email: lqi1@tulane.edu;

and Yan Zheng, Department of Cardiology Zhongshan Hospital, State Key Laboratory of Genetic Engineering School of Life Sciences, Human Phenome Institute, Fudan University, 2005 Songhu Road, Shanghai 200438, China. Email: yan_zheng@fudan.edu.cn

Fax: +1 504 988 3548; Tel: +1 504 988 7259

Abstract

Background Epidemiology studies suggested that low birthweight was associated with a higher risk of hypertension in later life. However, little is known about the causality of such associations.

Methods and Results In our study, we evaluated the causal association of low birthweight with adulthood hypertension following a standard analytic protocol using the study-level data of 183,433 participants from 60 studies (CHARGE-BIG consortium), as well as that with blood pressure using publicly available summary-level genome-wide association data from EGG consortium of 153,781 participants, ICBP consortium and UK Biobank cohort together of 757,601 participants. We used seven SNPs as the instrumental variable in the study-level analysis and 47 SNPs in the summary-level analysis. In the study-level analyses, decreased birthweight was associated with a higher risk of hypertension in adults (the odds ratio per 1 standard deviation (SD) lower birthweight, 1.22; 95%CI 1.16 to 1.28), while no association was found between genetically instrumented birthweight and hypertension risk (instrumental odds ratio for causal effect per 1 SD lower birthweight, 0.97; 95%CI 0.68 to 1.41). Such results were consistent with that from the summary-level analyses, where the genetically determined low birthweight was not associated with blood pressure measurements either. One SD lower genetically determined birthweight was not associated with systolic blood pressure ($\beta = -0.76$, 95% CI -2.45 to 1.08 mmHg), 0.06 mmHg lower diastolic blood pressure ($\beta = -0.06$, 95% CI -0.93 to 0.87 mmHg), or pulse pressure ($\beta = -0.65$, 95% CI -1.38 to 0.69 mmHg, all $p > 0.05$).

Conclusion Our findings suggest that the inverse association of birthweight with hypertension risk from observational studies was not supported by large Mendelian randomization analyses.

Key Words: Birthweight; hypertension; blood pressure; Mendelian randomization; causal association

INTRODUCTION

Hypertension, defined as high in systolic blood pressure, diastolic blood pressure, or both above normal levels, is a leading risk factor for mortality and morbidity. In 2015, high systolic blood pressure was associated with the heaviest disease burden among risk factors—more than either smoking or obesity.(1) Worldwide, the estimated rate of death attributable to high systolic blood pressure (140 mmHg or more) was 106.3/100,000 persons in 2015, and the number of disability-adjusted life-years was 7.8 million.(2)

Over the past decades, epidemiology studies have provided emerging observational evidence for developmental origins for hypertension.(3) Low birthweight, a surrogate marker of intrauterine malnutrition and developmental stressors, has emerged as a potential risk factor for cardio-metabolic disorders, including hypertension in later life.(4, 5) Several lines of pathophysiological evidence have provided potential mechanisms including vascular dysfunction, reduced nephron numbers, sympathetic activation and neuroendocrine involved in the association of low birthweight with adulthood hypertension and blood pressure.(6) However, conventional observational studies are vulnerable to serious issues of confounding, reverse causality, inappropriate adjustment of current weight, and therefore are not able to make causal inference. Large-scaled meta-analyses of the observed associations between birthweight and hypertension in later life had reached controversial conclusions.(5, 7) Traditional clinical trials are unrealistic in such cases to assess the causality of these associations, necessitating other study designs.

Mendelian randomization (MR) is an emerging approach which takes advantage of genetic markers as instrumental variables (IVs) and therefore, potentially overcomes the limitations as mentioned above of observational studies and clinical trials. This approach exploits the fact that at meiosis individual genotypes are assigned randomly, and therefore, the effect of genetics on disease is free of confounding or reverse causality.(8) Birthweight has a significant genetic architecture, and approximately 15% of its variance can be attributed to fetal genetic variation,(9) although the intrauterine environment also has considerable influence. Recent genome-wide association studies (GWAS) have

identified seven variants(10) associated with birthweight, and such a list has expanded to 60 loci where fetal genotype was associated with birthweight.(9) These genetic variants can be used as a proxy for birthweight to examine whether low birthweight contributes causally to hypertension development.

In this study, we collected extensive study-level data from 60 studies with 183,433 participants (CHARGE-BIG consortium) and summary-level data from the Early Growth Genetics (EGG) consortium of 153,781 participants, the International Consortium of British Pensioners (ICBP) consortium and UK Biobank cohort (UKB) together of 757,601 participants, and explored the possible causal association of birthweight with adulthood blood pressure and hypertension using MR analyses. Because our study started earlier than the most recent published GWAS, which reported 60 loci of birthweight, we included the previous seven variants as the instrument variables in the analysis of study-level data, and 57 loci of birthweight in the analysis of summary-level data.

METHODS

Study design and instruments

We use MR analyses to assess the causal association of birthweight with blood pressure and hypertension risk, under three assumptions.(11) First, genetic variants used as an instrument must be associated with birthweight. Second, genetic variants must not be associated with confounders. Third, genetic variants must not be associated with hypertension or blood pressure independent of birthweight. The above-mentioned second and third assumptions jointly refer to independence from pleiotropy.

This study consisted of two parts (**Fig 1**). First, we estimated the causal association of birth weight with hypertension risk using study-level data from the Cohorts for Heart and Aging Research in Genomic Epidemiology-Birth Gene (CHARGE-BIG) Study, which included 60 cross-sectional and prospective cohort studies with a total of 180,056 participants. The details of CHARGE-BIG study have been described before.(12) In brief, we analyzed the data within

each study by standardized analytic methods using a genetic risk score (GRS) of the 7 single-nucleotide polymorphisms (SNPs) as an IV from an earlier GWAS of the EGG Consortium.⁽¹⁰⁾ Second, we explored the causal association of birth weight with systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) utilizing summary-level data from the EGG consortium (n=153,781),⁽⁹⁾ the UKB (n=458,577) and the ICBP consortium (n=299,024).⁽¹³⁾ Because neither UKB nor ICBP has hypertension as an existing categorical outcome in GWAS summary data, we included blood pressure measurements as the outcome variables in the summary-level analysis. A total of the available 57 SNPs or its proxies, a subset of the 60 SNPs reported by an updated result of EGG consortium,⁽⁹⁾ were used as the instrument for birth weight in the summary-level analysis.

All participants from CHARGE-BIG consortium provided written informed consent, and all participating studies received approval from local research ethics committees. The appendix (Supplemental Table 1) includes the description of all the included studies in CHARGE-BIG consortium in the analysis. Contributing studies received ethical approval from their respective institutional review boards.

Phenotypic measures

In the CHARGE-BIG consortium, Hypertension was defined as systolic blood pressure of 140 mmHg or higher, diastolic blood pressure of 90 mmHg or higher, or current use of antihypertensive medication. Birthweight was self-reported or collected from medical records, and information of covariates was collected in each study. The appendix (Supplemental Table 2) describes details about the methods used to collect information on birthweight and hypertension in each study. The detailed genome-wide analysis of blood pressure traits, including SBP, DBP and PP, among participants of European ancestry from UKB (14) and ICBP consortium (15, 16) have been described previously.⁽¹³⁾

Selection of SNPs and genetic risk scores

In the study-level analyses, to create the GRS of low birthweight we selected 7 SNPs (*CCNLI* rs900400, *ADCY5* rs9883204, *HMGA2* rs1042725, *CDKALI* rs6931514, *5q11.2* rs4432842, *LCORL* rs724577, *ADRB1* rs1801253) based on

findings from 69,308 participants of European descent by the EGG Consortium.(10) The genotyping information and the distribution of genotypes of these 7 SNPs in each study were described in Supplemental Tables 3 and 4. In a secondary analysis, we excluded 5 SNPs associated with blood pressure or significant confounders such as adult height and type 2 diabetes,(10) and included the rest two SNPs in the GRS. We constructed an externally weighted low birthweight GRS, weighted by the effect estimates reported in EGG GWAS (β is the change in z score of birthweight per birthweight-lowering allele from linear regression, adjusted for sex and gestational age where available, assuming an additive genetic model).(10)

For the summary-level data analysis, a total of 60 SNPs were reported to be associated with birth weight by a more recent report from EGG consortium,(9) of which 50 were available in UKB and ICBP consortium. For those SNPs that were not genotyped, we found proxies that are in high linkage disequilibrium with the corresponding SNP ($r^2 > 0.8$) according to the information from 1000 Genomes Project. Ultimately, 57 SNPs were used as the instrument to assess the causal association of birth weight with blood pressure measurements.

Statistical analysis

Study-level analyses

In the study-level analyses, each of the CHARGE-BIG studies analyzed the data following a standard analytic protocol. Generalized linear regression models of the association between GRS and hypertension were adjusted with age, sex, body mass index (BMI), total energy intake, and principal components for population stratification if available. With respect to the phenotypic analyses, logistic regression models with hypertension as outcome and birthweight as exposure were adjusted with age, sex, BMI, and other risk factors of hypertension if available, such as smoking status (current vs. former/never), physical activity (MET h/day or hours) (quintiles), total energy intake (kcal) (quintiles), and alcohol consumption (quintiles). Concerning the genetic effects on birthweight, the effect allele was the birthweight-lowering allele, as established by the EGG consortium.(10) We tested for association of the GRS with birthweight using linear

regression models, adjusting for sex, gestational age if available, and principal components for population stratification if available.

Within the CHARGE-BIG collaboration, formal MR analyses were conducted using the IV ratio method.(17) To assess the IV ratio for the effect of birthweight on hypertension, we divided the meta-analyzed association of birthweight GRS with hypertension by the association of birthweight GRS with birthweight. The variance for the IV ratio was estimated using a Taylor expansion.(18) The above analyses were repeated in the sex- and BMI (<25 kg/m², or ≥25 kg/m²)-stratified subgroups. To examine the strength of the GRS as an instrument, we calculated the F-statistic from the proportion of variation in the birthweight (R^2) explained by the allele score, controlling for covariates (age, sex, and principal components for population stratification) in the Nurses' Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS) cohorts. An F statistic greater than 10 is evidence of a strong instrument.(19)

To examine whether the SNPs for birthweight were associated with potential confounders, each birthweight-associated SNP was evaluated for pleiotropy associations with potential risk factors, including major lipids in 196,476 individuals (Global Lipids Genetics Consortium),(20) glycemic traits in 46,186 individuals without diabetes (Meta-Analyses of Glucose and Insulin-Related Traits Consortium),(21) type 2 diabetes in 110,452 individuals (Diabetes Genetics Replication and Meta-analysis),(22) BMI and waist-to-hip ratio adjusted for BMI in 224,459 individuals (Genetic Investigation of Anthropometric Traits),(23) and chronic kidney disease-defining traits in 175,579 individuals (24) (**Supplemental Fig. 1**).

In the presence of heterogeneity of association among studies, inverse variance-weighted random-effects models were used for meta-analyses; otherwise, fixed-effects models were used. Heterogeneity among studies was assessed with the I^2 statistic.(25-27) We found non-negligible heterogeneity between studies, in particular among the birthweight-hypertension associations, but also for the association between low birthweight GRS and birthweight ($I^2 > 0.25$).

Summary-level analyses

We extracted 57 beta-coefficients and standard errors of the SNP-birthweight associations from EGG consortium, and that of SNP-blood pressure associations from the ICBP consortium and UKB via GWAS catalog (<https://www.ebi.ac.uk/gwas/downloads/summary-statistics>). We computed individual MR estimates and standard errors by weighting the effect sizes based on the magnitude of the SNP-birthweight association.(28) We used the inverse variance-weighted (IVW) MR approach as the primary analysis, where the inverse variance weighted mean of ratio estimates from the multiple IVs is the IV estimate.(28) This approach assumes that IVs affect the outcome only through the exposure under consideration, and not via any alternative pathways.(28) Violation of this assumption implies horizontal pleiotropy of the IV, measured by the heterogeneity estimates of Cochran Q-derived $P < 0.05$, and it could bias the MR estimate. Thus, we further conducted several sensitivity analyses with different assumptions regarding the presence of pleiotropic genetic variants that may relate with the outcome independently of the exposure. For example, MR-Egger regression requires that the strengths of the instruments are independent of their direct associations with the outcome (11), and the weighted median method requires that at least half of the information for the MR analysis comes from valid instruments (29). The intercept of the MR-Egger regression is a measure of directional pleiotropy ($P < 0.05$ was considered significant) (11).

We carried out all the analyses with R version 3.2.3 (<http://www.r-project.org>).

RESULTS

The study-level results

In the study-level analysis, the analytic sample included 183,433 individuals from 60 cohort and case-control studies (**Fig. 2**, Supplemental Table 5). Twenty-four studies (51,568 participants) reported the GRS-birthweight associations; and 33 studies (109,735 participants) reported the GRS-hypertension associations. A total of 70,874 hypertensive participants and 61,933 normotensive controls provided hypertension-related data, and 50,626 participants

provided GRS-birthweight associations only. The majority of participants were of European (86%) and Asian (14%) ancestry (**Supplemental Table 5**).

Large scale GWAS consortia did not suggest that the seven SNPs were associated with potential hypertension risk factors, including circulating major lipids, fasting glucose and insulin, type 2 diabetes, BMI, waist-to-hip ratio, and chronic kidney disease (**Supplemental Fig. 1**). The low birthweight GRS was inversely associated with birthweight (**Fig. 3A**, each risk allele was associated with 0.02 standard deviation (SD) lower birthweight, and there was evidence for heterogeneity in such an association ($I^2=78\%$, $p<0.01$). The F-statistics for the score were both >18 using data from the NHS and the HPFS (**Supplemental Table 6**), indicating the GRS is a strong composite instrument.

In the meta-analysis of the CHARGE-BIG studies, lower birthweight was associated with a higher risk of hypertension in adults (**Table 1** and **Fig. 4**, odds ratio (OR) per 1 SD lower birthweight, 1.22, 95%CI 1.16 to 1.28). There was no significant association of the low birthweight GRS with hypertension risk (**Table 1** and **Fig. 3B**, OR per 1 risk allele of low birthweight: 1.00, 95%CI 0.99 to 1.01). The relationships of lower birthweight and low birthweight GRS with the risk of hypertension in both sexes and BMI status were consistent with those in the overall population (**Table 1**).

In the formal MR analysis, genetically instrumented birthweight was not associated with risk of hypertension (**Table 1** and **Fig. 4**, instrumental OR for causal effect per 1 SD lower birthweight: 0.97, 95%CI 0.68 to 1.41). Again, no association was seen in each sex or BMI status group (**Table 1**). The secondary analysis using two SNPs conservatively either showed no association between genetically instrumented birthweight and risk of hypertension (instrumental OR 1.12, 95%CI 0.66 to 1.89, **Supplemental Fig. 2**).

The summary-level results

In the random-effect IVW MR analyses using the 57 SNPs as the IVs, one SD lower genetically instrumented birthweight showed a trend of association with 0.76 mmHg lower SBP (95% CI, -2.45 to 1.08 mmHg), 0.06 mmHg lower DBP (95% CI, -0.93 to 0.87 mmHg), and 0.65 mmHg lower PP (95% CI, -1.38 to 0.69 mmHg), however, none

of these associations was significant (all $p > 0.05$, **Table 2**). No presentation for directional pleiotropy effects was detected by the MR-Egger intercept (SBP, $p=0.73$; DBP, $p=0.64$; PP, $p=0.90$; Table 2). Although there was evidence for horizontal pleiotropy of the IV (Cochran Q derived $p < 0.05$), the results from MR-Egger method and weighted median based method were consistent with that from IVW MR method for SBP, DBP and PP (**Table 2**). We further excluded 14 previously reported SNPs for blood pressure or hypertension, or used the 7 SNPs only as sensitivity analyses in order to be consistent with the study-level analyses, and in either situation low birthweight remained not associated with blood pressure measurements (Supplemental Table 7).

DISCUSSION

Numerous nutritional interventions have been effective in reducing the short-term risk of low birthweight and prematurity. Understanding the potential long-term benefits of such interventions is crucial to inform policy decisions to interrupt the developmental programming cycle and stem the growing epidemics of hypertension worldwide. With low birthweight related genetic loci as the IV, the results of our MR analysis provide evidence for a non-causal effect of low birthweight on a higher risk of hypertension and blood pressure measurements, suggesting that low birthweight might not be a casual risk factor for development of hypertension.

Evidence from observational studies of low birthweight and a higher risk of hypertension constitutes some most robust finding supporting the fetal origins of adult disease.(30) Barker and colleagues were the first to report that low birthweight was associated with a higher risk of cardiovascular disease.(31) Subsequently, Brenner and colleagues proposed that developmental programming in the kidney may reduce nephron number, which may result in a limited filtration surface area and reduced sodium excretion, and eventually development of hypertension.(32) Our observed inverse association of birthweight with hypertension risk was consistent with traditional observational studies, which were largely from Caucasians.(4, 33-36) In Chinese populations, intrauterine exposure to famine was related to a higher

1 risk of hypertension in adults,(37, 38) and such findings were indirectly consistent with our observational findings.

2 In our study, we did not observe an association of genetically determined birthweight with hypertension risk or
3 blood pressure measurements during adulthood. Our result is in line with that from the recent MR analysis from
4 UKB,(39) which also reported a null association of birthweight with blood pressure and hypertension risk. However, the
5 UKB analysis exclusively studied the Caucasian population in the UK, and our analysis included samples of Caucasians
6 and Asians from diverse populations and countries. It is worth mentioning the genetic correlation analyses of birthweight
7 with hypertension from the recent GWAS for birthweight.(9) This GWAS is in line with our findings that it suggested a
8 lack of genetic association between birthweight and blood pressure from linkage-disequilibrium score regression,
9 indicating that birthweight is not causal for hypertension risk and blood pressure as well. Consistently, a recent
10 Mendelian randomization study with a smaller sample size (n=5000) selecting instruments according this GWAS did not
11 found significant causal association between birth weight and hypertension either.(40, 41) Our study suggested a lack of
12 association of the genetic instruments of birthweight, and this observation did not implicate that a lack of association of
13 the intrauterine malnutrition and developmental stressors with hypertension risk. It is possible that the environment
14 determined lower birth weight might have an effect on the risk of hypertension, though it is beyond the scope of the
15 current analysis. Our findings should not be interpreted as to undermine the critical value of interventions improving
16 birthweight in order to lower the hypertension risk in later life.

17 Our study has several strengths. First, we carried out an IV analysis on the causality of birthweight on hypertension
18 and blood pressure using large and diverse populations. The large sample size might provide us with sufficient power to
19 estimate the causal effect of low birthweight on hypertension and blood pressure, and the diverse source of data allows
20 decent generalizability. Second, we used a standardized analysis protocol to collect study-level statistics within
21 CHARGE-BIG consortium, and it minimized the potential bias from different data analyses methods. Our data should be
22 interpreted with caution, and several limitations were related to the validity of the assumptions underlying the causal

interpretation of MR studies. First, for the instrument variable, in the study-level analyses we only used seven SNPs related with low birthweight instead of the 60 SNPs from the most recent GWAS,(9) however, in our summary-level analyses, we included 57 available SNPs. The results were consistent in study-level and summary-level analyses, as well as in different sensitivity analyses, providing further support for the noncausal association of birthweight with blood pressure and hypertension risk. Second, though we have minimized the horizontal pleiotropic effects using existing large consortia data and different MR sensitivity analysis methods, future studies are warranted to take into consideration other essential factors that may be causatively related with intrauterine growth restriction. Such factors may include prenatal factors such as gestational week and postnatal behaviors such as breastfeeding. Third, we did not include the maternal genetic background in the analysis, which may affect the intrauterine environment and therefore, birthweight. Recent GWAS suggested that several maternal genetic variants influence fetal birthweight independently of the fetal genome.(42) Therefore, future MR studies with IVs from both maternal and fetal aspects of adult hypertension risk and blood pressure would provide new insights. Fourth, we did not collect blood pressure measurements from individual studies in the study-level analysis. Blood pressure may have a more significant measurement error, and the estimated association with blood pressure may be weaker compared that with hypertension.(43) Nevertheless, we used the blood pressure measurements in the summary-level analyses and reached consistent conclusion. Fifth, in the study-level analyses, we defined hypertension according to the previous definition(44) not the one currently proposed(45) by the American Heart Association, as the study was designed and conducted before the new definition issued. Canalization is one possible explanation for our results, because the low birthweight allele score might have led to biological adaptations during development (8). Furthermore, we assumed that the association of genetically determined birthweight with hypertension risk and blood pressure is linear; however, such assumption may not be correct because both the extreme low or high birthweights influence hypertension risk.

The associations of low birthweight, as an indicator of intrauterine growth restriction, with a higher hypertension

risk and blood pressure measurements in adults from observational studies were not supported by our MR analyses.

These findings suggest that the observational association of birthweight with hypertension risk in later life could be the result of confounding.

Acknowledgments We thank the staff and the participants of the studies for their valuable contributions for their important contributions.

Funding This work was supported by Shanghai Municipal Science and Technology Major Project (No. 2017SHZDZX01) and the National Key Research and Development Program of China (No. 2016YFC1304801). YZ was supported by the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning. For the funding information of each study within CHARGE-BIG consortium, please see Supplemental Table 8.

Compliance with ethical standards

Conflict of Interest There are no relevant conflicts of interest on the part of any study authors. There are no relevant financial, personal or professional relationships with other people or organizations to disclose.

References

1. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388(10053):1659-724. doi:10.1016/S0140-6736(16)31679-8
2. Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. *JAMA*. 2017;317(2):165-82. doi:10.1001/jama.2016.19043
3. Luyckx VA, Brenner BM. Birth weight, malnutrition and kidney-associated outcomes--a global concern. *Nat Rev Nephrol*. 2015;11(3):135-49. doi:10.1038/nrneph.2014.251
4. Curhan GC, Chertow GM, Willett WC, et al. Birth weight and adult hypertension and obesity in women. *Circulation*. 1996;94(6):1310-5.
5. Mu M, Wang SF, Sheng J, et al. Birth weight and subsequent blood pressure: a meta-analysis. *Arch Cardiovasc Dis*. 2012;105(2):99-113. doi:10.1016/j.acvd.2011.10.006
6. Bruno RM, Faconti L, Taddei S, Ghiadoni L. Birth weight and arterial hypertension. *Curr Opin Cardiol*. 2015;30(4):398-402. doi:10.1097/hco.0000000000000180
7. Huxley R, Neil A, Collins R. Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure? *Lancet*. 2002;360(9334):659-65. doi:10.1016/S0140-6736(02)09834-3
8. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol*. 2003;32(1):1-22.
9. Horikoshi M, Beaumont RN, Day FR, et al. Genome-wide associations for birth weight and correlations with adult disease. *Nature*. 2016;538(7624):248-52. doi:10.1038/nature19806
10. Horikoshi M, Yaghootkar H, Mook-Kanamori DO, et al. New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. *Nature Genetics*. 2013;45(1):76-82. doi:10.1038/ng.2477
11. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International Journal of Epidemiology*. 2015;44(2):512-25.
12. Birth-gene (BIG) Study working group. Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study. *JAMA Network Open*. 2019;2(9):e1910915. doi:10.1001/jamanetworkopen.2019.10915
13. Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nature Genetics*. 2018;50(10):1412-25. doi:10.1038/s41588-018-0205-x
14. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Medicine*. 2012;9(10):e1001779.
15. Wain Louise V, Vaez A, Jansen R, et al. Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney. *Hypertension*. 2017;70(3):e4-e19. doi:10.1161/HYPERTENSIONAHA.117.09438
16. Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*. 2011;478(7367):103-9. doi:10.1038/nature10405
17. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med*. 2008;27(8):1133-63. doi:10.1002/sim.3034
18. Thomas DC, Lawlor DA, Thompson JR. Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. *Ann Epidemiol*. 2007;17(7):511-3. doi:10.1016/j.annepidem.2006.12.005
19. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. *International journal of epidemiology*. 2011;40(3):755-64. doi:10.1093/ije/dyr036
20. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. *Nature Genetics*. 2013;45(11):1274-83. doi:10.1038/ng.2797

21. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nature Genetics*. 2010;42(2):105-16. doi:10.1038/ng.520
22. Mahajan A, Go MJ, Zhang W, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nature Genetics*. 2014;46(3):234-44. doi:10.1038/ng.2897
23. Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature*. 2015;518(7538):187-96. doi:10.1038/nature14132
24. Pattaro C, Teumer A, Gorski M, et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nature Communications*. 2016;7(1):10023. doi:10.1038/ncomms10023
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Bmj*. 2003;327(7414):557-60. doi:10.1136/bmj.327.7414.557
26. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. *Bmj*. 2007;335(7626):914-6. doi:10.1136/bmj.39343.408449.80
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-58. doi:10.1002/sim.1186
28. Burgess S, Butterworth A, Thompson SG. Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data. *Genet. Epidemiol*. 2013;37(7):658-65. doi:10.1002/gepi.21758
29. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet. Epidemiol*. 2016;40(4):304-14. doi:10.1002/gepi.21965
30. Lenfant C. Low birth weight and blood pressure. *Metabolism: clinical and experimental*. 2008;57 Suppl 2:S32-5. doi:10.1016/j.metabol.2008.07.013
31. Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. *Lancet*. 1986;1(8489):1077-81.
32. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? *American journal of hypertension*. 1988;1(4 Pt 1):335-47.
33. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Ascherio AL, Stampfer MJ. Birth weight and adult hypertension, diabetes mellitus, and obesity in US men. *Circulation*. 1996;94(12):3246-50.
34. Bergvall N, Iliadou A, Johansson S, et al. Genetic and shared environmental factors do not confound the association between birth weight and hypertension: a study among Swedish twins. *Circulation*. 2007;115(23):2931-8. doi:10.1161/CIRCULATIONAHA.106.674812
35. Li Y, Ley SH, VanderWeele TJ, et al. Joint association between birth weight at term and later life adherence to a healthy lifestyle with risk of hypertension: a prospective cohort study. *BMC medicine*. 2015;13:175. doi:10.1186/s12916-015-0409-1
36. Johansson S, Iliadou A, Bergvall N, Tuvemo T, Norman M, Cnattingius S. Risk of high blood pressure among young men increases with the degree of immaturity at birth. *Circulation*. 2005;112(22):3430-6. doi:10.1161/CIRCULATIONAHA.105.540906
37. Li Y, Jaddoe VW, Qi L, et al. Exposure to the Chinese famine in early life and the risk of hypertension in adulthood. *Journal of hypertension*. 2011;29(6):1085-92. doi:10.1097/HJH.0b013e328345d969
38. Huang C, Li Z, Wang M, Martorell R. Early life exposure to the 1959-1961 Chinese famine has long-term health consequences. *The Journal of nutrition*. 2010;140(10):1874-8. doi:10.3945/jn.110.121293
39. Zannetti D, Tikkanen E, Gustafsson S, Priest JR, Burgess S, Ingelsson E. Birthweight, Type 2 Diabetes Mellitus, and Cardiovascular Disease: Addressing the Barker Hypothesis With Mendelian Randomization. *Circulation. Genomic and precision medicine*. 2018;11(6):e002054. doi:10.1161/CIRCGEN.117.002054
40. Zeng P, Zhou X. Causal Association between Birth Weight and Adult Diseases: Evidence from a Mendelian Randomisation Analysis. *Frontiers in Genetics*. 2019;10:618.

-
- 1 41. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases
2 and 3,000 shared controls. *Nature*. 2007;447(7145):661.
- 3 42. Beaumont RN, Warrington NM, Cavadino A, et al. Genome-wide association study of offspring birth weight in 86
4 577 women identifies five novel loci and highlights maternal genetic effects that are independent of fetal genetics. *Human*
5 *molecular genetics*. 2018;27(4):742-56. doi:10.1093/hmg/ddx429
- 6 43. Vimalaewaran KS, Cavadino A, Berry DJ, et al. Association of vitamin D status with arterial blood pressure and
7 hypertension risk: a mendelian randomisation study. *The lancet. Diabetes & endocrinology*. 2014;2(9):719-29.
8 doi:10.1016/S2213-8587(14)70113-5
- 9 44. Carretero OA, Oparil S. Essential hypertension: part I: definition and etiology. *Circulation*. 2000;101(3):329-35.
- 10 45. Whelton PK, Carey RM, Aronow WS, et al. 2017
11 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation,
12 and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart
13 Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2018;71(19):e127-
14 e248.




Fig. 1. Study Design

The data sources included study-level data from the Cohorts for Heart and Aging Research in Genomic Epidemiology-Birth Gene (CHARGE-BIG) Study, which included 60 cross-sectional and prospective cohort studies, and summary-level data from the Early Growth Genetics (EGG) consortium, International Consortium of British Pensioners (ICBP) consortium and UK Biobank.




Fig. 2 Flow chart showing the sample sizes available at each stage of the meta-analyses in CHARGE-BIG consortium.





Fig. 3 Meta-analysis of associations of low birth weight genetic risk score with birth weight (A) and hypertension (B) using the study-level data from CHARGE-BIG consortium. Betas were the associations of low birth weight genetic risk score with outcome, per risk allele for low birth weight. CI, confidence interval.



1

2 **Fig. 4** Mendelian Randomization triangulation for hypertension using study-level data from CHARGE-BIG consortium.

3 IV, instrumental variable; OR, odds ratio; and CI, confidence interval.

Table 1. Summary of instrumental variable estimates (odds ratio) and 95% confidence intervals, with the low birthweight genetic risk score as an instrumental variable from the study-level data from CHARGE-BIG consortium

	Low birthweight with hypertension, per 1 SD lower birthweight (observational odds ratio)	Low birthweight genetic risk score with hypertension, per risk allele for low birthweight	Instrumental variable estimate for causal effect, per 1 SD lower birthweight (instrumental odds ratio)
Overall population	1.22 (1.16, 1.28)	1.00 (0.99, 1.01)	0.97 (0.68, 1.41)
Sex			
Men	1.19 (1.05, 1.35)	1.01 (0.99, 1.02)	0.76 (0.41, 1.43)
Women	1.25 (1.14, 1.37)	0.99 (0.98, 1.01)	1.31 (0.63, 2.72)
BMI, kg/m²			
<25	1.24 (1.15, 1.33)	1.00 (0.99, 1.02)	0.83 (0.41, 1.67)
≥25	1.19 (1.12, 1.26)	1.00 (0.99, 1.01)	1.01 (0.54, 1.91)

SD, standard deviation; and BMI, body mass index.

Table 2. Mendelian Randomization of Birth Weight with Blood Pressure using summary level data from EGG consortium, ICBP consortium and UK Biobank cohort.

	β (95%CI)	P-value
Systolic blood pressure, mmHg		
Inverse variance weighted method	-0.76 (-2.45, 1.08)	0.40
Weighted median based method	-0.37 (-0.77, 0.52)	0.33
MR-Egger method	-1.78 (-2.09, 0.10)	0.56
MR-Egger regression ¹	0.03 (-0.17, 0.18)	0.73
Diastolic blood pressure, mmHg		
Inverse variance weighted method	-0.06 (-0.93, 0.87)	0.89
Weighted median based method	-0.28 (-0.52, 0.39)	0.22
MR-Egger method	-0.77 (-4.20, 1.83)	0.62
MR-Egger regression ¹	0.02 (-0.10, 0.10)	0.64
Pulse pressure, mmHg		
Inverse variance weighted method	-0.65 (-1.38, 0.69)	0.23
Weighted median based method	0.05 (-0.55, 0.58)	0.86
MR-Egger method	-0.87 (-5.07, 1.95)	0.63
MR-Egger regression ¹	0.01 (-0.10, 0.10)	0.90

¹ Intercept of MR Egger regression, which is a measure of directional pleiotropy ($P < 0.05$ was considered significant).